COMPANY

Ceramedix

ceramedix.com ↗ · Mid-Atlantic

Keywords: gastroenterology diabetes mellitus diabetic retinopathy diabetic macular edema

Profile checked Oct 10, 2026

8NIH grants

Timeline

Jan 3, 2025 Grant Government grant — SBIR: $992,960 (annual award, as published), announced Jan 3, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Jan 3, 2025 Government grant — SBIR: $992,960 (annual award, as published), announced Jan 3, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 8

Annual award amounts. Total $9.2M.

2025 NIH contract (government contract; not a grant and not an investment round) 75N93023C00015-P00006-9999-1 FY2025: $1,267,019 awarded for that fiscal year; activity N01 (OTHER_NIH); PI DIMMLER III, CHARLES; recipient as written: CERAMEDIX HOLDING, LLC, NEW YORK, source ↗
Feb 5, 2024 NIH award 5R44AI106283-07 FY2024: $1,002,340 awarded for that fiscal year; activity R44 (SBIR); PI VID, GALINA; recipient as written: CERAMEDIX HOLDING, LLC, NEW YORK, NY. Non-Clinical Pharmacology of CX-01 source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93023C00015-P00003-9999-1 FY2024: $1,427,108 awarded for that fiscal year; activity N01 (OTHER_NIH); PI DIMMLER III, CHARLES; recipient as written: CERAMEDIX HOLDING, LLC, NEW YORK, source ↗
Feb 15, 2023 NIH award 2R44AI106283-06A1 FY2023: $1,011,743 awarded for that fiscal year; activity R44 (SBIR); PI VID, GALINA; recipient as written: CERAMEDIX HOLDING, LLC, NEW YORK, NY. Non-Clinical Pharmacology of CX-01 source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93023C00015-0-9999-1 FY2023: $1,529,485 awarded for that fiscal year; activity N01 (OTHER_NIH); PI DIMMLER III, CHARLES; recipient as written: CERAMEDIX HOLDING, LLC, NEW YORK, NY. source ↗
Apr 16, 2020 NIH award 5R44AI106283-05 FY2020: $994,084 awarded for that fiscal year; activity R44 (SBIR); PI TINKELENBERG, ARTHUR; recipient as written: CERAMEDIX HOLDING, LLC, NEW YORK, NY. Development of Anti-ceramide scFv as source ↗
Apr 24, 2019 NIH award 5R44AI106283-04 FY2019: $968,115 awarded for that fiscal year; activity R44 (SBIR); PI FUKS, ZVI Y.; recipient as written: CERAMEDIX HOLDING, LLC, NEW YORK, NY. Development of Anti-ceramide scFv as Mitigato source ↗
Apr 25, 2018 NIH award 2R44AI106283-03A1 FY2018: $993,013 awarded for that fiscal year; activity R44 (SBIR); PI FUKS, ZVI Y.; recipient as written: CERAMEDIX HOLDING, LLC, NEW YORK, NY. Development of Anti-ceramide scFv as Mitiga source ↗